# Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

> **NCT02051335** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 27 (actual)

## Conditions studied

- Memory Impairment
- Alzheimer's Disease

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Roflumilast placebo
- **DRUG:** Donepezil
- **DRUG:** Donepezil placebo
- **DRUG:** Scopolamine

## Key facts

- **NCT ID:** NCT02051335
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02051335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02051335, "Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02051335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*